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Abstract: Dual oral antiplatelet therapy, aspirin plus thienopyridine, has permitted a rapid 
increase in the use of coronary intervention procedures. Clopidogrel is the thienopyridine of 
choice for dual antiplatelet therapy in patients treated with percutaneous coronary intervention. 
However, there are two issues with clopidogrel: (1) clopidogrel’s antiplatelet activity is delayed 
because the drug needs to be metabolized into its active form and (2) variability in patient 
response to clopidogrel has been demonstrated. To overcome these shortcomings of clopidogrel, 
new more potent inhibitors of P2Y12 receptors, which have a more rapid onset of action have 
been introduced for clinical evaluation. This article is a nonexhaustive review of the literature and 
concentrates on prasugrel, a third-generation, oral thienopyridine. The purpose is to summarize 
the current knowledge about the benefits and risks of prasugrel and to outline the most prudent 
strategies for the drug’s clinical use.
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Introduction
Recognition that activation of platelets, rather than the coagulation pathway, increases 
the risk of stent-associated thrombosis1 has led to the strategy of platelet inhibition with 
a combination of antiplatelet drugs with complementary mechanisms of action as an 
adjuvant therapy for percutaneous coronary intervention (PCI). Complementary and 
independent mechanisms, irreversible inhibition of the thromboxane A2, adenosine 
diphosphate (ADP) and glycoprotein IIb/IIIa platelet recruitment pathways, have 
produced cumulative decreases in thrombotic events with acceptable bleeding risks 
following stent implantation.2
Dual oral antiplatelet therapy, aspirin plus thienopyridine, has permitted a rapid 
increase in the use of coronary intervention procedures. PCIs have become the most 
commonly performed coronary revascularization procedures, accounting for approxi-
mately 60% of all revascularizations.3,4 Therefore, optimizing the outcome after the 
procedure through the use of adjunctive antiplatelet therapy, which provides maximum 
protection against thrombosis without increasing the risk of bleeding, can have a 
substantial impact on cardiovascular morbidity and mortality.
Thienopyridines
Thienopyridine derivatives irreversibly modify platelet P2Y12 receptors by covalently 
binding to cysteine residues of the receptor.5 The proportion of ADP receptors 
sensitive to the effects of thienopyridines is limited to 60%–70%.6 Currently there 
are two equally effective thienopyridines,7,8 ticlopidine and clopidogrel, available Vascular Health and Risk Management 2009:5 476
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for clinical use. Clopidogrel is better tolerated and more 
convenient to use (once-daily dosing) compared to 
ticlopidine.7 As a result, clopidogrel has almost replaced 
ticlopidine as the thienopyridine of choice for dual anti-
platelet therapy in patients treated with PCI.9 Clopidogrel 
decreases the incidence of coronary stent thrombosis; addi-
tionally it has been approved and has proven beneficial in the 
reduction of myocardial infarction, stroke, and vascular death 
in patients with atherosclerotic vascular disease.10 Beyond its 
anti-aggregation effect, clopidogrel decreases the expression 
of activated platelet-dependent inflammatory markers such as 
the CD40 ligand (a potent stimulus of vascular inflammation) 
and CD62 P-selectin in patients undergoing PCI.11,12
Clopidogrel limitations
Clopidogrel is an inactive prodrug of thienopyridine, which 
needs to be metabolized by the hepatic cytochrome P450 
enzymes (CYP450) into the active compound.13 However, 
only a small percentage of administered clopidogrel is metab-
olized by CYP450. The majority of clopidogrel is hydro-
lyzed to an inactive derivative that accounts for 85% of 
the clopidogrel-related compounds circulating in plasma.14 
The need for metabolization delays the blocking of P2Y12 
platelet receptors and thus, the drug’s antiplatelet activity. 
Additionally, patient variability to clopidogrel has been 
demonstrated and shown to follow a typical bell-shaped 
or normal curve distribution.15,16 The variable inhibition of 
platelet aggregation (IPA) observed with clopidogrel seems 
to result from lower exposure to the active metabolite.17 
Therefore, all factors that influence drug absorption18 and 
metabolic activation (ie, CYP450 activity)19,20 can affect 
drug effectiveness.
In the clopidogrel-efficacy curve, a relation between the 
pre- and post-treatment platelet reactivity index was found.21 
Clopidogrel’s capacity to inhibit platelet ADP-induced 
platelet activation was found to be limited. This can be 
partially explained by the greater proportion of low responders 
to clopidogrel in patients with diabetes who have enhanced 
platelet reactivity.20,22 Therefore, the degree of platelet 
suppression after clopidogrel was lower in patients under-
going PCI, for acute coronary syndrome, than in patients with 
stable coronary artery disease.21,23,24
Patients on clopidogrel therapy with lower responsiveness 
to clopidogrel had an increased rate of recurrent cardiovas-
cular events.25,26 The best antiplatelet effects occurred at 
loading doses of 600 mg and maintenance doses of 150 mg a 
day.27 Nonresponsiveness to high loading doses has also been 
reported in clinical studies. One of the largest of these studies 
(N = 804) reported that “nonresponsiveness” to a clopidogrel 
600 mg loading dose was a strong independent predictor of 
stent thrombosis in patients receiving drug-eluting stents.28
To overcome shortcomings of clopidogrel, new more 
potent inhibitors of P2Y12 receptors, with a more rapid onset 
of action have been introduced for clinical evaluation, these 
include: prasugrel, cangrelor, and AZD 6140.
Prasugrel
Drug characteristics
Prasugrel is also a prodrug and must be converted to an 
active form before binding irreversibly to the P2Y12 receptor 
and inhibiting platelet aggregation for the life of the platelet. 
Prasugrel is rapidly absorbed and extensively metabo-
lized. Prasugrel is quickly hydrolyzed to pharmacologically 
inactive thiolactone (R-95913).29,30 Thiolactone (R-95913) 
is further metabolized (oxidized) by intestinal and hepatic 
CYP-450 enzymes, which leads to formation of the active 
metabolite. In humans, renal excretion accounts for approxi-
mately 70% prasugrel metabolites.29,30 The antiplatelet effects 
of prasugrel are time- and dose-dependent.
Onset of action and antiplatelet efficacy
Conversion of clopidogrel to its active metabolite is a 2-step, 
CYP450-dependent process.14 However, prasugrel requires 
only one CYP450-dependent oxidative step to generate the 
thiol-containing active metabolite.30 This difference may 
underlie the more rapid metabolic conversion and onset of 
action of prasugrel compared with clopidogrel.31 The active 
metabolite of prasugrel was detected in plasma within 15 min 
of dosing and reached a maximum plasma concentration 
approximately 30 min after dosing.29,31
In a randomized, crossover, ex vivo study, healthy subjects 
received a single loading dose of prasugrel (60 mg) or 
clopidogrel (300 mg).31 Inhibition of platelet aggregation with 
prasugrel was evident after 15 min. Platelet inhibitory effects 
of a 60 mg loading dose of prasugrel 30 min after adminis-
tration was greater than the maximum antiplatelet effects of 
clopidogrel 12 hours after a 300 mg loading dose.
In patients with stable atherosclerosis, prasugrel (60 mg 
loading dose) achieved quicker and greater inhibition of 
ADP-induced platelet aggregation, compared to a 600 mg 
loading dose of clopidogrel.17 The difference in the IPA 
between clopidogrel and prasugrel was observed in as little 
as 30 min following drug administration. Within 30 minutes, 
prasugrel had achieved antiplatelet effects superior to the 
maximum antiplatelet effects attained by 600 mg of clopido-
grel over the 24-hour long observation period.Vascular Health and Risk Management 2009:5 477
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The data from the PRINCIPLE-TIMI 44 (Prasugrel 
in Comparison to Clopidogrel for Inhibition of Platelet 
Activation and Aggregation- Thrombolysis in Myocardial 
Infarction)32 study extend the results to patients undergoing 
cardiac catheterization for planned percutaneous coronary 
intervention. This trial compared the same dose regimen of 
prasugrel with high-dose clopidogrel (600 mg loading dose 
and 150 mg/d maintenance dose). Substantially and statisti-
cally significant greater platelet inhibition with prasugrel 
was observed at all time points studied during the loading 
dose and maintenance dose phases. Prasugrel was more 
potent and consistent in comparison to clopidogrel in the 
PCI setting.
The active metabolites of prasugrel and clopidogrel have 
similar potency at the platelet level.33 The greater potency 
of prasugrel to inhibit platelet P2Y12 receptors in patients 
with coronary artery disease, compared with clopidogrel, 
has been linked to more efficient generation of prasugrel’s 
active metabolite, to higher peak plasma levels and greater 
exposure of platelets to the active metabolite.17,31
inter-individual variability
Studies including patients with coronary artery disease 
have documented inter-individual variability relative to 
clopidogrel’s capacity to inhibit platelet aggregation.15,16,34 
A substantial proportion (24%35 nonresponders with the 
clopidogrel 300 mg and 11% nonresponders with the clopi-
dogrel 600 mg)34 of the patients undergoing elective PCI were 
evaluated as nonresponders to clopidogrel treatment. The 
proportion of patients, with limited clopidogrel efficacy, was 
even higher in patients with acute myocardial infarction.36 
The percentage of prasugrel nonresponders, in patients with 
stable coronary artery disease (using the same definition 
for nonresponse; IPA  20% in response to 20 µM ADP), 
was only 3% after the 40 and 60 mg doses of prasugrel.37 
A crossover study in healthy, aspirin-free subjects demon-
strated that all individuals who responded poorly to the 
clopidogrel 300 mg achieved robust platelet inhibition when 
switched to prasugrel.31
Translation of prasugrel benefits 
into the clinical outcomes
The degree of suppression of platelet activity achieved 
through the use of antithrombotic agents should be balanced 
against the risk of atherothrombotic events.38 Accordingly 
the target population for prasugrel includes patients at high 
risk of thrombo-occlusive events:
•  patients undergoing PCI for STE myocardial infarction,
•  patients at risk of stent thrombosis and patients after stent 
thrombosis,
•  diabetics undergoing PCI,
•  patients with the presence of genetic variants related to 
nonresponsiveness to clopidogrel.
Patients undergoing PCI for STE 
myocardial infarction
The TRITON-TIMI 38 (TRial to assess Improvement in 
Therapeutic Outcomes by optimizing platelet inhibition 
with prasugrel)39 found that in patients with acute coronary 
syndromes scheduled for PCI, prasugrel (60 mg loading dose 
and a 10 mg daily maintenance dose), compared with approved 
doses of clopidogrel (300 mg loading dose and a 75 mg daily 
maintenance dose), yielded significantly reduced rates of 
ischemic events. The primary efficacy end point (death from 
cardiovascular causes, nonfatal myocardial infarction, or 
nonfatal stroke) occurred in 12.1% of patients receiving clopi-
dogrel and 9.9% of patients receiving prasugrel (p  0.001). 
There were also significant reductions in the prasugrel group 
relative to rates of (i) myocardial infarction (9.7% for clopido-
grel vs 7.4% for prasugrel; p  0.001), (ii) urgent target-vessel 
revascularization (3.7% vs 2.5%; p  0.001), and (iii) stent 
thrombosis (2.4% vs 1.1%; p  0.001). Death from cardiovas-
cular causes and overall mortality did not differ significantly 
between treatment groups. However, this clinical benefit was 
accompanied by a significant increase in the risk of serious 
bleeding with prasugrel. Major bleeding was observed in 2.4% 
of patients receiving prasugrel and in 1.8% of patients receiving 
clopidogrel (p = 0.03). In addition, the prasugrel group showed 
an increased rate of life-threatening bleeding (1.4% vs 0.9%; 
p = 0.01) and fatal bleeding (0.4% vs 0.1%; p = 0.002). A post 
hoc analysis of the study data identified three subgroups that 
had greater bleeding risk than the overall studied population: 
(i) patients with a history of stroke or transient ischemic attack, 
(ii) age  75 years, and (iii) body weight  60 kg.
TRITON-TIMI 38 was designed to compare clopidogrel 
with prasugrel in patients undergoing PCI over the entire 
spectrum of acute coronary syndrome with moderate-to-
high-risks. Montalescot and colleagues40 recently published 
a prespecified analysis from the subgroup with STE 
myocardial infarctions. Patients with STE myocardial infarc-
tion underwent primary PCI within 12 hours of symptom 
onset or secondary PCI within 14 days of myocardial 
infarction for ongoing or recurrent ischemia or as part of 
a routine invasive strategy.39 The significant reduction in 
primary ischemic endpoint with prasugrel was consistent 
with that in the population with unstable angina or non-STE Vascular Health and Risk Management 2009:5 478
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myocardial infarction. At 30 days, 6.5% of patients in the 
prasugrel arm had met the primary endpoint compared with 
9.5% in the clopidogrel arm (p = 0.0017). Cardiovascular 
death (p = 0.0469) and all causes of death (p = 0.0445) were 
also significantly reduced with prasugrel. After 15 months, 
rates of myocardial infarction and stent thrombosis remained 
significantly reduced with prasugrel. Differences in all-
cause and cardiovascular deaths between the groups lost 
statistical significance. The benefit from the more intensive 
platelet inhibitory effects associated with prasugrel was 
more pronounced in patients at higher risk. Patients with 
anterior myocardial infarctions had significantly (p = 0.0003) 
lower incidence of primary endpoint with prasugrel (9.8%) 
compared with clopidogrel (16.3%). In individuals with 
nonanterior myocardial infarctions, treatment effects did not 
differ with regard to the primary endpoint (9.9% clopidogrel 
vs 10.1% prasugrel; p = 0.8749). In the subgroup with STE 
myocardial infarctions, no difference was reported between 
prasugrel and clopidogrel in thrombolysis in myocardial 
infarction (TIMI) major bleeding, life-threatening bleeding 
or intracranial hemorrhage. Prasugrel was associated with 
a significantly increased risk for TIMI major bleeding after 
coronary artery bypass graft surgery at 15 months, compared 
with clopidogrel (18.8% vs 2.7%; p = 0.0033).
No randomized studies have been identified that 
compared prasugrel with clopidogrel 600 mg in patients with 
acute coronary syndromes. The ongoing TRILOGY ACS 
(Targeted Platelet Inhibition to Clarify the Optimal Strategy 
to Medically Manage Acute Coronary Syndromes) study41 is 
comparing the tolerability and efficacy of a reduced dose of 
prasugrel (30 mg loading dose, 5 mg/d maintenance dose) 
with those of clopidogrel (300 mg loading dose, 75 mg/d 
maintenance dose) in reducing the risk of cardiovascular 
death, heart attack, or stroke in patients with an acute coro-
nary syndrome who are to be medically managed without 
planned revascularization.
Patients at risk of stent thrombosis 
and patients after stent thrombosis
Despite combined antiplatelet therapy, stent thrombosis 
persists at a rate of 0.5%–2% in elective interventions, and up 
to 6% in patients with acute coronary syndromes.42 In cases of 
immediate reperfusion therapy by means of emergency PCI, 
patients with stent thrombosis have progressed to a major myo-
cardial infarction, with a consequential significant decline in 
left ventricular function – a strong negative predictor of long-
term survival.42–45 Clinical and angiographic predictors of stent 
thrombosis have been identified; the most important predictors 
involved a poor post-procedural result such as inadequate 
stent expansion, residual dissection, and inappropriate IPA43,44 
Therefore, improvement in stenting techniques and proper 
IPA represent variable of causal importance. Unfortunately, 
patient-related factors including diabetes mellitus, extent of 
coronary artery disease, and renal failure are not modifiable.
In the TRITON-TIMI 38, the overall mortality rate for 
patients with stent thrombosis was 26%.45 In the same study, 
prasugrel, compared with the approved dose of clopidogrel, 
reduced the rate of stent thrombosis by 52% (p  0.001). The 
reduction in stent thrombosis was consistent across multiple 
subgroups with respect to baseline characteristics (age, sex, 
acute coronary syndrome presentation, creatinine clearance, 
diabetes, or previous myocardial infarction) and treatment 
characteristics (glycoprotein IIb/IIIa use, stent length, and 
presence of bifurcation stenting). The greatest absolute ben-
efits were seen in patients at higher risk for stent thrombosis, 
such as those with longer stents, bifurcation stents, impaired 
kidney function, and diabetes. Similar benefits of prasugrel 
were also seen in patients who received loading doses of 
study drugs before PCI (0.83% vs 2.23%; p = 0.002) or after 
the start of the procedure (1.24 vs 2.39%; p  0.0001).
Prasugrel reduced early (1.56% vs 0.64%; p  0.001) as 
well as late (0.82% vs 0.49%; p = 0.035) stent thrombosis in 
patients with acute coronary syndromes treated with either 
bare metal or drug-eluting stents.45 As the TRITON results 
demonstrate, the reduction in stent thrombosis by prasugrel 
should be weighed against its increased bleeding risk. How-
ever, subgroup analyses of the study39,45 found no increased 
bleeding risk with prasugrel, compared with clopidogrel, 
in patients at increased risk of stent thrombosis, such as 
diabetic patients and those with STE myocardial infarction. 
Recommendation of prasugrel for patients at high risk of stent 
thrombosis and in patients after stent thrombosis would be a 
very prudent strategy.
Diabetics undergoing PCI
Diabetes mellitus had an independent adverse effect on clinical 
outcomes in patients with coronary artery disease.39,47,48 
Diabetic patients have been shown to be poor responders 
to clopidogrel.20,49,50 Moreover, a high clopidogrel loading 
dose (600 mg) has been unable to satisfactorily inhibit 
platelet reactivity in diabetics undergoing elective PCI.20,51 
Prasugrel treatment (60 mg loading dose) resulted in a 
significantly lower proportion of diabetic patients with weak 
inhibition of ADP induced platelet activation, compared with 
600 mg of clopidogrel.51 The relationship between insuf-
ficient inhibition of platelet reactivity in diabetic patients, Vascular Health and Risk Management 2009:5 479
improving outcomes in patients undergoing PCi Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
on dual antiplatelet therapy, and a greater risk of adverse 
cardiovascular events has been demonstrated.50
Subgroup analysis from the TRITON-TIMI 3852 reports 
that the composite of cardiovascular death, myocardial infarc-
tion, and stroke, was significantly reduced with prasugrel, 
among subjects without diabetes mellitus (9.2% vs 10.6%; 
p = 0.02), and even more significantly in patients with diabetes 
mellitus (12.2% vs 17.0%; p  0.001), particularly in those 
taking insulin (14.3% vs 22.2%; p = 0.009). Although TIMI 
major hemorrhage was increased among subjects without 
diabetes mellitus on prasugrel (2.4%) vs clopidogrel (1.6%); 
p = 0.02), the rates were similar among subjects with diabetes 
mellitus (2.6% vs 2.5%; p = 0.81). In diabetic patients, the 
rate of TIMI major or minor bleeding was observed in 
5.3% with prasugrel and 4.3% with clopidogrel (p = 0.13). 
Therefore, the net clinical benefit with prasugrel was greater 
for patients with diabetes than for patients without diabetes 
(8% vs 26%). The greater platelet inhibition among patients 
with diabetes results in improved outcomes.
Patients with genetic variants 
related to nonresponsiveness 
to clopidogrel
Focusing on the relationship between genetics and therapy 
efficacy, could provide clinical advances, mostly for drugs 
with observed high inter-individual efficacy variability and 
life-threatening consequences resulting from inefficacy of 
these drugs. From this point of view, clopidogrel is an ideal 
candidate for pharmacogenetic studies which target the 
genetics behind clopidogrel inefficacy.
A significant reduction in clopidogrel antiplatelet effec-
tiveness, linked to the PlA2 polymorphism, has been found. 
A 600 mg loading dose of clopidogrel failed to acceptably 
inhibit platelet reactivity in patients with stable coronary 
artery disease undergoing elective PCI who were positive 
for this polymorphism.53
Genetic variants of CYP450 have been linked to a reduced 
exposure to the active drug metabolite, less platelet inhibi-
tion, and less protection from recurrent ischemic events in 
persons receiving clopidogrel.54,55 In patients with acute 
coronary syndromes treated with clopidogrel, the presence 
of CYP 2C19 reduced-function allele was associated with 
adverse clinical outcomes, including an increased death rate 
from cardiovascular causes, myocardial infarction, or stroke, 
especially among patients undergoing PCI.54,55 Notably, the 
rate of stent thrombosis was three times greater than that 
among noncarriers.55
The contribution of genetic testing relative to routine 
clinical practice remains unclear. Therefore, CYP 2C19 
reduced-function allele carriers are an optimal target popu-
lation for the study of new antithrombotic regimens, which 
includes prasugrel, the efficacy of which is unaffected by 
variability in CYP2C19 isoenzymes.56
Conclusion
The degree of suppression of platelet activity achieved 
through the use of antithrombotic agents should be balanced 
against the risk of atherothrombotic events. Prasugrel, in 
comparison to clopidogrel, is a more potent inhibitor of 
P2Y12 receptors, and has a more rapid onset of action. 
Accordingly the target population for prasugrel should 
include patients at high risk of thrombo-occlusive events, eg, 
patients undergoing percutaneous coronary intervention for 
STE myocardial infarction, patients at risk of stent thrombo-
sis or patients after stent thrombosis, diabetics undergoing 
PCI, or patients with the presence of genetic variants related 
to nonresponsiveness to clopidogrel.
The Committee for Medicinal Products for Human Use of 
the European Medicines Agency issued a positive opinion and 
recommended approval of prasugrel. Thereafter, the European 
Commission granted marketing approval of prasugrel (Efient, 
Lilly/Daiichi Sankyo) for the prevention of atherothrombotic 
events in patients with acute coronary syndromes undergoing 
PCI.57 Prasugrel will be marketed in European countries 
as early as April 2009. The initial, worldwide, launch of 
prasugrel took place in the UK. A positive nod from the US 
Food and Drug Administration is expected soon.58
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